Wall Street analysts expect Teligent Inc (NASDAQ:TLGT) to report earnings of ($0.01) per share for the current quarter, Zacks reports. Two analysts have issued estimates for Teligent’s earnings. The highest EPS estimate is $0.00 and the lowest is ($0.02). Teligent also posted earnings of ($0.01) per share in the same quarter last year. The firm is expected to announce its next quarterly earnings report on Tuesday, August 14th.
On average, analysts expect that Teligent will report full-year earnings of $0.02 per share for the current year, with EPS estimates ranging from ($0.02) to $0.05. For the next fiscal year, analysts forecast that the company will report earnings of $0.28 per share, with EPS estimates ranging from $0.20 to $0.35. Zacks’ EPS calculations are an average based on a survey of analysts that that provide coverage for Teligent.
Teligent (NASDAQ:TLGT) last posted its earnings results on Tuesday, May 8th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.01). Teligent had a negative return on equity of 27.25% and a negative net margin of 28.98%. The firm had revenue of $14.55 million during the quarter, compared to the consensus estimate of $15.62 million.
Several research analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Teligent from a “hold” rating to a “sell” rating in a report on Thursday, May 3rd. Canaccord Genuity set a $4.00 price objective on shares of Teligent and gave the company a “hold” rating in a report on Thursday, March 15th. Finally, ValuEngine upgraded shares of Teligent from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $7.00.
Teligent stock opened at $3.71 on Friday. The company has a quick ratio of 1.69, a current ratio of 2.73 and a debt-to-equity ratio of 3.07. The company has a market capitalization of $197.46 million, a PE ratio of -19.53 and a beta of 0.77. Teligent has a 12-month low of $2.43 and a 12-month high of $9.36.
Institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its holdings in shares of Teligent by 225.7% in the first quarter. JPMorgan Chase & Co. now owns 33,731 shares of the company’s stock valued at $274,000 after acquiring an additional 23,376 shares in the last quarter. Two Sigma Investments LP bought a new stake in Teligent during the fourth quarter worth approximately $123,000. Spark Investment Management LLC bought a new stake in Teligent during the first quarter worth approximately $162,000. UBS Asset Management Americas Inc. boosted its holdings in Teligent by 282.7% during the fourth quarter. UBS Asset Management Americas Inc. now owns 51,034 shares of the company’s stock worth $185,000 after buying an additional 37,700 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its holdings in Teligent by 26.1% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 74,300 shares of the company’s stock worth $270,000 after buying an additional 15,400 shares in the last quarter. Institutional investors and hedge funds own 62.10% of the company’s stock.
Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.
Get a free copy of the Zacks research report on Teligent (TLGT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.